Pharma: Astra Zeneca's breast cancer pill fails in crucial study
Compared to standard treatment, the medication was not able to slow the progression of the disease any more. The result could dampen optimism for the medication.
Astra Zeneca's breast cancer pill Camizestrant failed to slow disease progression better than standard treatment in an advanced study. The study tested Camizestrant in patients with recurrent or metastatic breast cancer who had not received prior treatment. The company will publish the data at a later time. Camizestrant is a hormone therapy that aims to prevent estrogen from binding to cancer cells and promoting growth. The US FDA approved Camizestrant on September 4 based on a smaller patient group study.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
